0001104659-23-118780.txt : 20231115 0001104659-23-118780.hdr.sgml : 20231115 20231115171335 ACCESSION NUMBER: 0001104659-23-118780 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20231109 ITEM INFORMATION: Entry into a Material Definitive Agreement ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20231115 DATE AS OF CHANGE: 20231115 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Newcourt Acquisition Corp CENTRAL INDEX KEY: 0001849475 STANDARD INDUSTRIAL CLASSIFICATION: BLANK CHECKS [6770] IRS NUMBER: 000000000 STATE OF INCORPORATION: E9 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-40929 FILM NUMBER: 231411529 BUSINESS ADDRESS: STREET 1: 2201 BROADWAY, SUITE 705 CITY: OAKLAND STATE: CA ZIP: 94612 BUSINESS PHONE: 27 83 294 3837 MAIL ADDRESS: STREET 1: 2201 BROADWAY, SUITE 705 CITY: OAKLAND STATE: CA ZIP: 94612 8-K 1 tm2330863d1_8k.htm FORM 8-K
false 0001849475 00-0000000 0001849475 2023-11-09 2023-11-09 0001849475 NCACU:UnitsEachConsistingOfOneClassOrdinaryShareParValue0.0001PerShareAndOnehalfOfOneRedeemableWarrantMember 2023-11-09 2023-11-09 0001849475 NCACU:ClassOrdinarySharesParValue0.0001PerShareIncludedAsPartOfUnitsMember 2023-11-09 2023-11-09 0001849475 NCACU:RedeemableWarrantsEachExercisableForOneClassOrdinaryShareFor11.50PerShareIncludedAsPartOfUnitsMember 2023-11-09 2023-11-09 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

United States

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

Form 8-K

 

Current Report

 

Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): November 15, 2023 (November 9, 2023)

 

Newcourt Acquisition Corp

(Exact name of registrant as specified in its charter)

 

Cayman Islands   001-40929   N/A
(State or other jurisdiction of
incorporation) 		  (Commission
File Number) 		  (I.R.S. Employer
Identification No.)

 

2201 Broadway, Suite 705
Oakland, CA		   94612
(Address of principal executive offices)   (Zip Code)

 

Registrant’s telephone number, including area code (657) 271-4617

 

Not Applicable

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

x Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of Each Class   Trading Symbol(s)   Name of each exchange on which
registered
Units, each consisting of one Class A ordinary share, par value $0.0001 per share, and one-half of one Redeemable Warrant   NCACU   The Nasdaq Stock Market LLC
         
Class A ordinary shares, par value $0.0001 per share, included as part of the units   NCAC   The Nasdaq Stock Market LLC
         
Redeemable Warrants, each exercisable for one Class A ordinary share for $11.50 per share, included as part of the units   NCACW   The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company x

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

 

 

 

 

 

 

Item 1.01. Entry into a Material Definitive Agreement.

 

Amendment to Business Combination Agreement

 

As previously disclosed, on July 31, 2023, Newcourt Acquisition Corp (“NCAC” or “Newcourt”) entered into an Amended and Restated Business Combination Agreement (the “Business Combination Agreement”) with Newcourt SPAC Sponsor LLC, a Delaware limited liability company (“Sponsor”), Psyence Group Inc., a corporation organized under the laws of Ontario, Canada (“Parent”), Psyence Biomedical Ltd., a corporation organized under the laws of Ontario, Canada (“Pubco,” and after the closing of the Merger (defined below), the “Combined Company”), Psyence (Cayman) Merger Sub, a Cayman Islands exempted company and a direct and wholly owned subsidiary of Pubco (“Merger Sub”), Psyence Biomed Corp., a corporation formerly organized under the laws of British Columbia, Canada and continued under the laws of Ontario, Canada, and Psyence Biomed II Corp., a corporation organized under the laws of Ontario, Canada (“Psyence”) in connection with the proposed business combination between the parties that was previously announced on January 13, 2023. The Business Combination Agreement provides for the following transaction structure: (i) Parent will contribute Psyence to Pubco in a share for share exchange (the “Company Exchange”) and (ii) immediately following the Company Exchange, Merger Sub will merge with and into NCAC, with NCAC being the surviving company in the merger (the “Merger”) and each outstanding ordinary share of NCAC will convert into the right to receive one common share of Pubco.

 

On November 9, 2023, the parties to the Business Combination Agreement entered into the First Amendment to the Amended and Restated Business Combination Agreement (the “Amendment”), which amended the Business Combination Agreement to clarify that each private placement warrant of NCAC will be converted into a public warrant of Pubco upon closing of the Merger.

 

Other than as expressly modified by the Amendment, the Business Combination Agreement remains in full force and effect. The foregoing description of the Amendment does not purport to be complete and is subject to, and qualified in its entirety by reference to, the full text of the Amendment, which is attached as Exhibit 2.1 hereto and incorporated herein by reference.

 

Item 7.01. Regulation FD Disclosure.

 

On November 15, 2023, Parent issued a press release announcing, among other things, the effectiveness of the registration statement on Form F-4 (the “Registration Statement”) filed by Pubco in connection with the proposed business combination. A copy of the press release is attached hereto as Exhibit 99.1 and incorporated by reference herein.

  

The information set forth in this Item 7.01 is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended (the “Securities Act”), or the Exchange Act, except as expressly set forth by specific reference in such filing.

 

 

 

Additional Information and Where to Find It

 

In connection with the proposed business combination, the Registration Statement was filed by Pubco with the SEC and includes a preliminary proxy statement / prospectus with respect to the proposed business combination. The definitive proxy statement / prospectus and other relevant documents will be mailed to shareholders of Newcourt as of November 13, 2023, the record date established for voting on the proposed business combination. Shareholders of Newcourt and other interested persons are advised to read, when available, the preliminary proxy statement / prospectus, the definitive proxy statement / prospectus and amendments thereto because these documents will contain important information about Newcourt, Psyence and the proposed business combination and the other parties thereto. Shareholders will also be able to obtain copies of the Registration Statement and the proxy statement / prospectus, without charge, by directing a written request to: Newcourt Acquisition Corp, 2201 Broadway, Suite 705, Oakland, CA 94612. These documents, once available, and Newcourt’s annual and other reports filed with the SEC can also be obtained, without charge, at the SEC’s internet site (http://www.sec.gov).

 

No Offer or Solicitation

 

This communication is for informational purposes only and is not intended to and does not constitute, or form a part of, an offer, invitation or the solicitation of an offer or invitation to purchase, otherwise acquire, subscribe for, sell or otherwise dispose of any securities, or the solicitation of any vote or approval in any jurisdiction, pursuant to the proposed business combination or otherwise, nor shall there be any sale, issuance or transfer of securities in any jurisdiction in contravention of applicable law. 

 

Participants in the Solicitation

 

Newcourt, Psyence, the other parties to the Business Combination Agreement, and their respective directors and executive officers, other members of management and employees may be considered participants in the solicitation of proxies with respect to the potential transaction described in this communication under the rules of the SEC. Information about the directors and executive officers of Newcourt is set forth in Newcourt’s filings with the SEC. Information regarding other persons who may, under the rules of the SEC, be deemed participants in the solicitation of the shareholders in connection with the potential transaction and a description of their interests will be set forth in the Registration Statement when it is filed with the SEC. These documents can be obtained free of charge from the sources indicated above.

  

Forward Looking Statements

 

This communication contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about future financial and operating results, our plans, objectives, expectations and intentions with respect to future operations, products and services; and other statements identified by words such as “will likely result,” “are expected to,” “will continue,” “is anticipated,” “estimated,” “believe,” “intend,” “plan,” “projection,” “outlook” or words of similar meaning.

 

Forward-looking statements in this communication include statements regarding the intended closing of the proposed business combination, the meeting of the closing conditions to the proposed business combination, the trading of Pubco securities on the Nasdaq and the execution of the clinical trial within the context of palliative care. These forward looking statements are based on a number of assumptions, including the assumptions that the closing conditions to the proposed business combination will be met, that Newcourt will obtain the necessary regulatory and shareholder approvals to complete the proposed business combination and that there will be access to capital to execute on Psyence’s strategy There are numerous risks and uncertainties that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, among others: the inability to complete the proposed business combination; the inability to recognize the anticipated benefits of the proposed business combination; demand for the Combined Company’s securities being less than anticipated; fluctuations in the price of Newcourt’s common shares, any further delays in the proposed business combination due to additional amendments to the Business Combination Agreement; and Newcourt not raising the investment amount expected, or any funds at all. Actual results and future events could differ materially from those anticipated in such information. Nothing in this communication should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. Except as required by law, Newcourt and Psyence do not intend to update these forward-looking statements.

 

 

 

Newcourt and Psyence make no medical, treatment or health benefit claims about the Combined Company’s proposed products. The efficacy of psilocybin, psilocybin analogues, or other psychedelic compounds or nutraceutical products remains the subject of ongoing research. There is no assurance that the use of psilocybin, psilocybin analogues, or other psychedelic compounds or nutraceuticals can diagnose, treat, cure or prevent any disease or condition. Vigorous scientific research and clinical trials are needed. Psyence Biomed has not completed the clinical trials for the use of its proposed products. Any references to quality, consistency, efficacy, and safety of potential products do not imply that Psyence or the Combined Company verified such in clinical trials or that the Combined Company will complete such trials. If the Combined Company cannot obtain the approvals or research necessary to commercialize its business, it may have a material adverse effect on the Combined Company’s performance and operations.

 

The foregoing list of factors is not exhaustive. You should carefully consider the foregoing factors and the other risks and uncertainties described in the “Risk Factors” section of the Registration Statement referenced above and other documents filed by Newcourt and Pubco from time to time with the SEC. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. There can be no assurance that the data contained herein is reflective of future performance to any degree. You are cautioned not to place undue reliance on forward-looking statements as a predictor of future performance as projected financial information and other information are based on estimates and assumptions that are inherently subject to various significant risks, uncertainties and other factors, many of which are beyond our control. Forward-looking statements speak only as of the date they are made, and Newcourt and Psyence disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of developments occurring after the date of this communication or other circumstances. Forecasts and estimates regarding Psyence’s industry and end markets are based on sources we believe to be reliable, however there can be no assurance these forecasts and estimates will prove accurate in whole or in part. Annualized, pro forma, projected and estimated numbers are used for illustrative purpose only, are not forecasts and may not reflect actual results.

 

Item 9.01 Financial Statements and Exhibits.

 

(d) Exhibits

 

Exhibit No.   Description
2.1   First Amendment to the Amended and Restated Business Combination Agreement, dated as of November 9, 2023, by and among Newcourt Acquisition Corp, Newcourt SPAC Sponsor LLC, Psyence Group Inc., Psyence Biomedical Ltd., Psyence (Cayman) Merger Sub, Psyence Biomed Corp. and Psyence Biomed II Corp.
99.1   Press Release, dated November 15, 2023.
104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Dated: November 15, 2023

 

  NEWCOURT ACQUISITION CORP
     
  By: /s/ Marc Balkin
    Name:  Marc Balkin
    Title: Chief Executive Officer

 

 

 EX-2.1 2 tm2330863d1_ex2-1.htm EXHIBIT 2.1

Exhibit 2.1

 

FIRST AMENDMENT TO AMENDED AND RESTATED BUSINESS COMBINATION AGREEMENT

 

This First Amendment to the Amended and Restated Business Combination Agreement (this “Amendment”), dated as of November 9, 2023, is made and entered into by and among Newcourt Acquisition Corp, a Cayman Islands exempted company (“SPAC”), Newcourt SPAC Sponsor LLC, a Delaware limited liability company (the “Sponsor”), Psyence (Cayman) Merger Sub, a newly incorporated Cayman Islands exempted company (“Merger Sub”), Psyence Group Inc., a corporation organized under the laws of Ontario, Canada (“Parent”), Psyence Biomed II Corp., a corporation organized under the laws of Ontario, Canada (“Target”), Psyence Biomed Corp., a corporation formerly organized under the laws of British Columbia, Canada and continued under the laws of Ontario, Canada (“Original Target”) and Psyence Biomedical Ltd., a corporation organized under the laws of Ontario, Canada and a wholly-owned subsidiary of the Parent (“NewCo”).

 

WHEREAS, SPAC, Sponsor, Merger Sub, Parent, Target, Original Target and NewCo previously entered into that certain Amended and Restated Business Combination Agreement, dated as of July 31, 2023 (the “Agreement”); capitalized terms used herein but not defined herein shall have the meanings ascribed thereto in the Agreement; and

 

WHEREAS, Section 12.1 of the Agreement provides that the Agreement may not be amended or modified except by an instrument in writing signed by each of Sponsor, SPAC, the Parent, the Target and NewCo; and

 

WHEREAS, the parties hereto wish to amend the Agreement as set forth herein.

 

NOW, THEREFORE, in consideration of the foregoing and the mutual covenants hereinafter set forth, the parties hereto agree as follows:

 

1. Amendments.

 

(a) Section 3.2(d) of the Agreement is hereby amended by deleting it in its entirety and replacing it with the following:

 

“(d)            Treatment of SPAC Warrants.

 

(i)            Each Public Warrant and Private Placement Warrant that is outstanding and unexercised immediately prior to the Effective Time shall be converted into and become a warrant to purchase NewCo Common Shares (“NewCo Warrants”), and NewCo shall assume each such Public Warrant and Private Placement Warrant in accordance with its terms (as in effect as of the date of this Agreement). All rights with respect to SPAC Shares under Public Warrants and Private Placement Warrants assumed by NewCo shall thereupon be converted into rights with respect to the NewCo Common Shares underlying the NewCo Warrants. Accordingly, from and after the Effective Time: (A) each NewCo Warrant assumed by NewCo may be exercised solely for NewCo Common Shares; (B) the number of NewCo Common Shares subject to each NewCo Warrant assumed by NewCo shall be the same number of SPAC Shares that were subject to such Public Warrant or Private Placement Warrant immediately prior to the Effective Time; (C) the exercise price for the NewCo Common Shares issuable upon exercise of each NewCo Warrant shall be the same as the applicable exercise price in effect immediately prior to the Effective Time; and (D) any restriction on the exercise of any Public Warrant or Private Placement Warrant assumed by NewCo shall continue in full force and effect and the term, exercisability, vesting schedule and other provisions of such Public Warrant or Private Placement Warrant shall otherwise remain unchanged; provided, however, that to the extent provided under the terms of a Public Warrant or Private Placement Warrant, as applicable, such Public Warrant or Private Placement Warrant assumed by NewCo in accordance with this Section 3.2(d)(i) shall, in accordance with its terms, be subject to further adjustment as appropriate to reflect any stock split, division or subdivision of shares, stock dividend, reverse stock split, consolidation of shares, reclassification, recapitalization or other similar transaction with respect to NewCo Common Shares subsequent to the Effective Time.

 

 

 

(ii)            As consideration for the NewCo Warrants issued pursuant to this Section 3.2(d) hereof, SPAC shall issue such number of ordinary shares of SPAC to NewCo as SPAC reasonably determines has an aggregate fair market value equal to the aggregate fair market value of such NewCo Warrants.”

 

(b) Section 9.14 of the Agreement is hereby amended by deleting the third sentence thereof in its entirety.

 

2. Effect on Agreement. Other than as specifically set forth herein, all other terms and provisions of the Agreement shall remain unaffected by the terms of this Amendment, and shall continue in full force and effect in accordance with their respective terms. Each reference in the Agreement to “this Agreement” shall mean the Agreement as amended by this Amendment, and as hereinafter amended or restated.

 

3. Counterparts. This Amendment may be executed and delivered in one or more counterparts and by fax, email or other electronic transmission, each of which shall be deemed an original and all of which shall be considered one and the same agreement.

 

4. Successors and Assigns. This Amendment shall be binding upon and inure solely to the benefit of the parties hereto and their respective successors and permitted assigns.

 

5. Amendment. This Amendment may not be amended or modified except by an instrument in writing signed by, or on behalf of, all of the parties hereto.

 

6. Governing Law. This Amendment shall be governed by, and construed in accordance with, the laws of the State of Delaware applicable to contracts executed in and to be performed in that State.

 

7. Entire Agreement. This Amendment, the Agreement, the Ancillary Agreements and the Confidentiality Agreement (together with the Disclosure Letters and Exhibits to the Agreement) constitute the entire agreement among the parties hereto with respect to the subject matter hereof, and supersede all prior and contemporaneous understandings and agreements, both written and oral, with respect to such subject matter.

 

[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK]

 

 

 

IN WITNESS WHEREOF, the parties hereto have duly executed and delivered this Amendment as of the date first written above.

 

  NEWCOURT ACQUISITION CORP
     
  By: /s/ Marc Balkin
  Name: Marc Balkin
  Title: Chief Executive Officer
   
  NEWCOURT SPAC SPONSOR LLC
     
  By: Tabula Rasa Ltd
  Its: Manager
  By: Fiducia Trustees Ltd.
  Its: Sole Corporate Director
  By: /s/ Carl Linde
  Name: Carl Linde
  Title: Director
   
  PSYENCE GROUP INC.
     
  By: /s/ Neil Maresky
  Name: Neil Maresky
  Title: CEO and Director
   
  PSYENCE BIOMED II CORP.
     
  By: /s/ Neil Maresky
  Name: Neil Maresky
  Title: CEO and Director
   
  PSYENCE BIOMED CORP.
     
  By: /s/ Neil Maresky
  Name: Neil Maresky
  Title: CEO
   
  PSYENCE BIOMEDICAL LTD.
     
  By: /s/ Neil Maresky
  Name: Neil Maresky
  Title: CEO and Director
   
  PSYENCE (CAYMAN) MERGER SUB
     
  By: /s/ Neil Maresky
  Name: Neil Maresky
  Title: Sole Director

 

 

 EX-99.1 3 tm2330863d1_ex99-1.htm EXHIBIT 99.1

 

Exhibit 99.1

 

PSYENCE GROUP ANNOUNCES SEC EFFECTIVENESS OF F-4 FOR PROPOSED BUSINESS COMBINATION BETWEEN SUBSIDIARY AND NASDAQ-LISTED NEWCOURT ACQUISITION CORP

 

 

TORONTO, ON, NOVEMBER 15, 2023 – Psyence Group Inc. (CSE:PSYG), a clinical-stage life science biotechnology company pioneering the use of nature-derived psilocybin in mental health and wellbeing (“Psyence”), and Newcourt Acquisition Corp (Nasdaq: NCAC) (“Newcourt”), a special purpose acquisition company today announced that the registration statement on Form F-4 (the “Registration Statement”), filed by Psyence Biomedical Ltd. (“Pubco”) with the Securities and Exchange Commission (“SEC”) was declared effective by the SEC on November 13, 2023. The Registration Statement was filed in connection with the previously announced business combination between Psyence Biomed Corp (“Psyence Biomed”), a wholly owned subsidiary of Psyence, and Newcourt. Pursuant to the Amended and Restated Business Combination Agreement, prior to the closing of the business combination (the “Business Combination”), Psyence will contribute Psyence Biomed, its therapeutics division, to Pubco, which is intended to become a reporting issuer in the United States.

  

The Business Combination values Psyence Biomed at a pre-money equity value of USD$50 million and the parties intend to close the Business Combination within two business days following satisfaction of the requisite closing conditions and approvals contained in the Business Combination Agreement. Following the closing of the Business Combination, Pubco’s common shares are anticipated to trade under the Nasdaq ticker “PBM”. The registration statement is available through the SEC’s website at www.sec.gov.

  

Dr Neil Maresky, the CEO of Psyence Group Inc. stated, “The significant milestone of receiving effectiveness is one step closer to a listing on a US national security exchange and enhancing our corporate profile in the U.S., as we aim to commence our phase IIb Clinical Trial using nature-derived psilocybin in Palliative Care.”

 

Maxim Group LLC is acting as financial advisor to Psyence. WeirFoulds LLP is acting as Canadian legal advisor and Ellenoff Grossman & Schole LLP is acting as U.S. legal advisor to Psyence. McDermott Will & Emery is acting as U.S. legal advisor to Newcourt.

  

Psyence further announced that it has granted stock options to eligible participants under its Stock Option Plan to purchase an aggregate of 6,104,043 common shares of Psyence Group Inc. at an exercise price of $0.06 per share. 3,887,377 options have an expiry date of December 31, 2025, 1,800,000 options have an expiry date of June 30, 2026 and 416,666 options have an expiry date of December 31, 2027.

 

 

 

 

Additional Information and Where to Find It

 

In connection with the proposed Business Combination, the Registration Statement was filed by Pubco with the SEC and includes a preliminary proxy statement/prospectus with respect to the proposed Business Combination. The definitive proxy statement/prospectus and other relevant documents will be mailed to shareholders of Newcourt as of November 13, 2023, the record date established for voting on the proposed Business Combination. Shareholders of Newcourt and other interested persons are advised to read, when available, the preliminary proxy statement/prospectus, the definitive proxy statement/prospectus and amendments thereto because these documents will contain important information about Newcourt, Psyence and the proposed Business Combination and the other parties thereto. Shareholders will also be able to obtain copies of the Registration Statement and the proxy statement/prospectus, without charge, by directing a written request to: Newcourt Acquisition Corp, 2201 Broadway, Suite 705, Oakland, CA 94612. These documents, once available, and Newcourt’s annual and other reports filed with the SEC can also be obtained, without charge, at the SEC’s internet site (http://www.sec.gov).

 

No Offer or Solicitation

 

This communication is for informational purposes only and is not intended to and does not constitute, or form a part of, an offer, invitation or the solicitation of an offer or invitation to purchase, otherwise acquire, subscribe for, sell or otherwise dispose of any securities, or the solicitation of any vote or approval in any jurisdiction, pursuant to the proposed Business Combination or otherwise, nor shall there be any sale, issuance or transfer of securities in any jurisdiction in contravention of applicable law.

 

Participants in the Solicitation

 

Newcourt, Psyence, the other parties to the Amended and Restated Business Combination Agreement, and their respective directors and executive officers, other members of management and employees may be considered participants in the solicitation of proxies with respect to the potential transaction described in this communication under the rules of the SEC. Information about the directors and executive officers of Newcourt is set forth in Newcourt’s filings with the SEC. Information regarding other persons who may, under the rules of the SEC, be deemed participants in the solicitation of the shareholders in connection with the potential transaction and a description of their interests will be set forth in the Registration Statement when it is filed with the SEC. These documents can be obtained free of charge from the sources indicated above.

 

Forward Looking Statements

 

This communication contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about future financial and operating results, our plans, objectives, expectations and intentions with respect to future operations, products and services; and other statements identified by words such as “will likely result,” “are expected to,” “will continue,” “is anticipated,” “estimated,” “believe,” “intend,” “plan,” “projection,” “outlook” or words of similar meaning.

 

 

 

Forward-looking statements in this communication include statements regarding the intended closing of the Business Combination, the meeting of the closing conditions to the Business Combination, the trading of Pubco securities on the Nasdaq and the execution of the clinical trial within the context of palliative care. These forward-looking statements are based on a number of assumptions, including the assumptions that the closing conditions to the Business Combination will be met, that Newcourt will obtain the necessary regulatory and shareholder approvals to complete the Business Combination and that there will be access to capital to execute on the Company's strategy. There are numerous risks and uncertainties that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, among others: the inability to complete the proposed Business Combination; the inability to recognize the anticipated benefits of the proposed Business Combination; demand for the Pubco’s securities being less than anticipated; fluctuations in the price of Newcourt’s ordinary shares, any further delays in the proposed Business Combination due to additional amendments to the Amended And Restated Business Combination Agreement; and Newcourt not raising the investment amount expected, or any funds at all. Actual results and future events could differ materially from those anticipated in such information. Nothing in this communication should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. Except as required by law, Newcourt and Psyence do not intend to update these forward-looking statements.

 

Newcourt and Psyence make no medical, treatment or health benefit claims about the proposed products under the therapeutics division of Psyence Biomed. The efficacy of psilocybin, psilocybin analogues, or other psychedelic compounds or nutraceutical products remains the subject of ongoing research. There is no assurance that the use of psilocybin, psilocybin analogues, or other psychedelic compounds or nutraceuticals can diagnose, treat, cure or prevent any disease or condition. Vigorous scientific research and clinical trials are needed. Psyence Biomed has not completed the clinical trials for the use of its proposed products. Any references to quality, consistency, efficacy, and safety of potential products do not imply that Psyence or Pubco verified such in clinical trials or that Pubco will complete such trials. If Pubco cannot obtain the approvals or research necessary to commercialize its business, it may have a material adverse effect on Pubco’s performance and operations.

 

The foregoing list of factors is not exhaustive. You should carefully consider the foregoing factors and the other risks and uncertainties described in the “Risk Factors” section of the Registration Statement referenced above and other documents filed by Newcourt and Pubco from time to time with the SEC. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. There can be no assurance that the data contained herein is reflective of future performance to any degree. You are cautioned not to place undue reliance on forward-looking statements as a predictor of future performance as projected financial information and other information are based on estimates and assumptions that are inherently subject to various significant risks, uncertainties and other factors, many of which are beyond our control. Forward-looking statements speak only as of the date they are made, and Newcourt and Psyence disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of developments occurring after the date of this communication or other circumstances. Forecasts and estimates regarding Psyence’s industry and end markets are based on sources we believe to be reliable, however there can be no assurance these forecasts and estimates will prove accurate in whole or in part. Annualized, pro forma, projected and estimated numbers are used for illustrative purpose only, are not forecasts and may not reflect actual results.

 

 

 

 

ABOUT PSYENCE GROUP: www.psyence.com

 

Psyence is a life science biotechnology company listed on the Canadian Securities Exchange (CSE: PSYG), with a focus on natural psychedelics. Psyence works with nature-derived psilocybin products for the healing of psychological trauma and its mental health consequences in the context of palliative care. Our name “Psyence” combines the words psychedelic and science to affirm our commitment to producing psychedelic medicines developed through evidence-based research.    

 

Informed by nature and guided by science, we built and operate one of the world’s first federally licensed commercial psilocybin mushroom cultivation and production facilities in Southern Africa. Our team brings international experience in both business and science and includes experts in mycology, neurology, palliative care, and drug development.  We work to develop advanced nature-derived psilocybin products for clinical research and development.

 

Our key divisions, Psyence Production and Psyence Therapeutics anchor an international collaboration, with operations in Canada, the United Kingdom, Southern Africa and Australia, and a presence in the United States.

 

Contact Information

 

Katherine Murphy, Investor Relations
Email: ir@psyence.com
Media Inquiries: media@psyence.com
General Information: info@psyence.com

 

 

 

 EX-101.SCH 4 ncacu-20231109.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.DEF 5 ncacu-20231109_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 6 ncacu-20231109_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Class of Stock [Axis] Units, each consisting of one Class A ordinary share, par value $0.0001 per share, and one-half of one Redeemable Warrant Class A ordinary shares, par value $0.0001 per share, included as part of the units Redeemable warrants, each exercisable for one Class A ordinary share for $11.50 per share, included as part of the units Statement [Table] Document Information [Line Items] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] Class A ordinary shares, par value $0.0001 per share, included as part of the units EX-101.PRE 7 ncacu-20231109_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 8 R1.htm IDEA: XBRL DOCUMENT v3.23.3
Cover
Nov. 09, 2023
Document Information [Line Items]  
Document Type 8-K
Amendment Flag false
Document Period End Date Nov. 09, 2023
Entity File Number 001-40929
Entity Registrant Name Newcourt Acquisition Corp
Entity Central Index Key 0001849475
Entity Tax Identification Number 00-0000000
Entity Incorporation, State or Country Code E9
Entity Address, Address Line One 2201 Broadway
Entity Address, Address Line Two Suite 705
Entity Address, City or Town Oakland
Entity Address, State or Province CA
Entity Address, Postal Zip Code 94612
City Area Code 657
Local Phone Number 271-4617
Written Communications true
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Emerging Growth Company true
Elected Not To Use the Extended Transition Period false
Units, each consisting of one Class A ordinary share, par value $0.0001 per share, and one-half of one Redeemable Warrant  
Document Information [Line Items]  
Title of 12(b) Security Units, each consisting of one Class A ordinary share, par value $0.0001 per share, and one-half of one Redeemable Warrant
Trading Symbol NCACU
Security Exchange Name NASDAQ
Class A ordinary shares, par value $0.0001 per share, included as part of the units  
Document Information [Line Items]  
Title of 12(b) Security Class A ordinary shares, par value $0.0001 per share, included as part of the units
Trading Symbol NCAC
Security Exchange Name NASDAQ
Redeemable warrants, each exercisable for one Class A ordinary share for $11.50 per share, included as part of the units  
Document Information [Line Items]  
Title of 12(b) Security Redeemable Warrants, each exercisable for one Class A ordinary share for $11.50 per share, included as part of the units
Trading Symbol NCACW
Security Exchange Name NASDAQ
XML 9 tm2330863d1_8k_htm.xml IDEA: XBRL DOCUMENT 0001849475 2023-11-09 2023-11-09 0001849475 NCACU:UnitsEachConsistingOfOneClassOrdinaryShareParValue0.0001PerShareAndOnehalfOfOneRedeemableWarrantMember 2023-11-09 2023-11-09 0001849475 NCACU:ClassOrdinarySharesParValue0.0001PerShareIncludedAsPartOfUnitsMember 2023-11-09 2023-11-09 0001849475 NCACU:RedeemableWarrantsEachExercisableForOneClassOrdinaryShareFor11.50PerShareIncludedAsPartOfUnitsMember 2023-11-09 2023-11-09 iso4217:USD shares iso4217:USD shares false 0001849475 00-0000000 8-K 2023-11-09 Newcourt Acquisition Corp E9 001-40929 2201 Broadway Suite 705 Oakland CA 94612 657 271-4617 true false false false Units, each consisting of one Class A ordinary share, par value $0.0001 per share, and one-half of one Redeemable Warrant NCACU NASDAQ Class A ordinary shares, par value $0.0001 per share, included as part of the units NCAC NASDAQ Redeemable Warrants, each exercisable for one Class A ordinary share for $11.50 per share, included as part of the units NCACW NASDAQ true false EXCEL 10 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 11 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 12 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.3 html 4 24 1 false 3 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://Newcourtacquisitioncorp.com/role/Cover Cover Cover 1 false false All Reports Book All Reports ncacu-20231109.xsd ncacu-20231109_def.xml ncacu-20231109_lab.xml ncacu-20231109_pre.xml tm2330863d1_8k.htm http://xbrl.sec.gov/dei/2023 true false JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "tm2330863d1_8k.htm": { "nsprefix": "NCACU", "nsuri": "http://Newcourtacquisitioncorp.com/20231109", "dts": { "schema": { "local": [ "ncacu-20231109.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "definitionLink": { "local": [ "ncacu-20231109_def.xml" ] }, "labelLink": { "local": [ "ncacu-20231109_lab.xml" ] }, "presentationLink": { "local": [ "ncacu-20231109_pre.xml" ] }, "inline": { "local": [ "tm2330863d1_8k.htm" ] } }, "keyStandard": 24, "keyCustom": 0, "axisStandard": 1, "axisCustom": 0, "memberStandard": 0, "memberCustom": 3, "hidden": { "total": 3, "http://xbrl.sec.gov/dei/2023": 3 }, "contextCount": 4, "entityCount": 1, "segmentCount": 3, "elementCount": 66, "unitCount": 3, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 30 }, "report": { "R1": { "role": "http://Newcourtacquisitioncorp.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "AsOf2023-11-09", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "tm2330863d1_8k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2023-11-09", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "tm2330863d1_8k.htm", "first": true, "unique": true } } }, "tag": { "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://Newcourtacquisitioncorp.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AnnualInformationForm", "presentation": [ "http://Newcourtacquisitioncorp.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r14" ] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyReport", "presentation": [ "http://Newcourtacquisitioncorp.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r13" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://Newcourtacquisitioncorp.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r2" ] }, "NCACU_ClassOrdinarySharesParValue0.0001PerShareIncludedAsPartOfUnitsMember": { "xbrltype": "domainItemType", "nsuri": "http://Newcourtacquisitioncorp.com/20231109", "localname": "ClassOrdinarySharesParValue0.0001PerShareIncludedAsPartOfUnitsMember", "presentation": [ "http://Newcourtacquisitioncorp.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Class A ordinary shares, par value $0.0001 per share, included as part of the units", "documentation": "Class A ordinary shares, par value $0.0001 per share, included as part of the units" } } }, "auth_ref": [] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementTable", "presentation": [ "http://Newcourtacquisitioncorp.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Statement [Table]" } } }, "auth_ref": [] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://Newcourtacquisitioncorp.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r10" ] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://Newcourtacquisitioncorp.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "NCACU_RedeemableWarrantsEachExercisableForOneClassOrdinaryShareFor11.50PerShareIncludedAsPartOfUnitsMember": { "xbrltype": "domainItemType", "nsuri": "http://Newcourtacquisitioncorp.com/20231109", "localname": "RedeemableWarrantsEachExercisableForOneClassOrdinaryShareFor11.50PerShareIncludedAsPartOfUnitsMember", "presentation": [ "http://Newcourtacquisitioncorp.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Redeemable warrants, each exercisable for one Class A ordinary share for $11.50 per share, included as part of the units" } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCountry", "presentation": [ "http://Newcourtacquisitioncorp.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://Newcourtacquisitioncorp.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "us-gaap_ClassOfStockDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfStockDomain", "presentation": [ "http://Newcourtacquisitioncorp.com/role/Cover" ], "auth_ref": [] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://Newcourtacquisitioncorp.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r2" ] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://Newcourtacquisitioncorp.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r6" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://Newcourtacquisitioncorp.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r8" ] }, "us-gaap_StatementClassOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementClassOfStockAxis", "presentation": [ "http://Newcourtacquisitioncorp.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Class of Stock [Axis]" } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://Newcourtacquisitioncorp.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r2" ] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://Newcourtacquisitioncorp.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r2" ] }, "dei_DocumentInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentInformationLineItems", "presentation": [ "http://Newcourtacquisitioncorp.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Information [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://Newcourtacquisitioncorp.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r2" ] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://Newcourtacquisitioncorp.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://Newcourtacquisitioncorp.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r12" ] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine3", "presentation": [ "http://Newcourtacquisitioncorp.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://Newcourtacquisitioncorp.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r7" ] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityReportingObligation", "presentation": [ "http://Newcourtacquisitioncorp.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r9" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://Newcourtacquisitioncorp.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r2" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://Newcourtacquisitioncorp.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r1" ] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://Newcourtacquisitioncorp.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPrimarySicNumber", "presentation": [ "http://Newcourtacquisitioncorp.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r14" ] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://Newcourtacquisitioncorp.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://Newcourtacquisitioncorp.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r15" ] }, "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentDescription", "presentation": [ "http://Newcourtacquisitioncorp.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://Newcourtacquisitioncorp.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://Newcourtacquisitioncorp.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r18" ] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://Newcourtacquisitioncorp.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r14" ] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://Newcourtacquisitioncorp.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://Newcourtacquisitioncorp.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://Newcourtacquisitioncorp.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r19" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://Newcourtacquisitioncorp.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://Newcourtacquisitioncorp.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://Newcourtacquisitioncorp.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r3" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://Newcourtacquisitioncorp.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://Newcourtacquisitioncorp.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r2" ] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "NoTradingSymbolFlag", "presentation": [ "http://Newcourtacquisitioncorp.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://Newcourtacquisitioncorp.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://Newcourtacquisitioncorp.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodStartDate", "presentation": [ "http://Newcourtacquisitioncorp.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAnnualReport", "presentation": [ "http://Newcourtacquisitioncorp.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r11", "r13", "r14" ] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://Newcourtacquisitioncorp.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r13" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://Newcourtacquisitioncorp.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://Newcourtacquisitioncorp.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r4" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://Newcourtacquisitioncorp.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://Newcourtacquisitioncorp.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://Newcourtacquisitioncorp.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r17" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://Newcourtacquisitioncorp.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CountryRegion", "presentation": [ "http://Newcourtacquisitioncorp.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityVoluntaryFilers", "presentation": [ "http://Newcourtacquisitioncorp.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://Newcourtacquisitioncorp.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://Newcourtacquisitioncorp.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://Newcourtacquisitioncorp.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r16" ] }, "NCACU_UnitsEachConsistingOfOneClassOrdinaryShareParValue0.0001PerShareAndOnehalfOfOneRedeemableWarrantMember": { "xbrltype": "domainItemType", "nsuri": "http://Newcourtacquisitioncorp.com/20231109", "localname": "UnitsEachConsistingOfOneClassOrdinaryShareParValue0.0001PerShareAndOnehalfOfOneRedeemableWarrantMember", "presentation": [ "http://Newcourtacquisitioncorp.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Units, each consisting of one Class A ordinary share, par value $0.0001 per share, and one-half of one Redeemable Warrant" } } }, "auth_ref": [] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAccountingStandard", "presentation": [ "http://Newcourtacquisitioncorp.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentRegistrationStatement", "presentation": [ "http://Newcourtacquisitioncorp.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r0" ] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12gTitle", "presentation": [ "http://Newcourtacquisitioncorp.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r5" ] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Extension", "presentation": [ "http://Newcourtacquisitioncorp.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r8": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r9": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r10": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r11": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r12": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r13": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r14": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r15": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r16": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r17": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r18": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r19": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 16 0001104659-23-118780-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001104659-23-118780-xbrl.zip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end